GLP-1 Drugs for PCOS: What a Systematic Review Says About Weight, Hormones, and Metabolism | Research

The takeaway

GLP-1 receptor agonists effectively reduce body weight and improve some metabolic and hormonal parameters in women with PCOS, especially when combined with metformin.

486 PCOS patients across 8 studies
GLP-1 drugs consistently reduced BMI, waist circumference, and visceral fat, with combination metformin therapy showing superior results

What the researchers found

Across 8 studies with 486 PCOS patients (ages 18-45, follow-up 12-32 weeks), GLP-1 receptor agonists consistently reduced BMI, waist circumference, fat mass, and visceral fat mass. Combined GLP-1 and metformin therapy produced greater reductions in these measurements compared to either treatment alone or other comparators.

GLP-1 agonists also improved some endocrine and metabolic parameters of PCOS, though the abstract notes the effects on these parameters "remain elusive" and vary across studies. The overall conclusion supports GLP-1 drugs as effective for weight reduction and metabolic improvement in PCOS, with combination therapy showing the most promise.

Why it matters

PCOS is the most common endocrine disorder in reproductive-age women, and weight loss is considered first-line treatment because it can improve nearly every aspect of the syndrome — from irregular periods to hormone imbalances to insulin resistance. But losing weight with PCOS is notoriously difficult. GLP-1 drugs offer a pharmacological tool to achieve meaningful weight loss, and this review suggests they may also directly improve the hormonal disturbances that characterize PCOS, making them a potentially powerful option for this underserved patient population.

The numbers in context

8 studies; 486 patients; ages 18-45; 12-32 week follow-up; reduced BMI, waist circumference, fat mass, visceral fat; combination therapy superior to monotherapy

How the study worked

Systematic review of longitudinal cohort studies from Ovid Medline, PubMed Central, and Cochrane Library (2015-2022). Included studies enrolled women diagnosed with PCOS per 2003 Rotterdam or 1990 NIH criteria. Evaluated GLP-1 receptor agonist monotherapy and GLP-1/metformin combination therapy effects on anthropometric, endocrine, and metabolic parameters.

Who was studied

486 lean and obese women aged 18-45 with PCOS diagnosed by Rotterdam or NIH criteria, across 8 studies with 12-32 week follow-up

What this study cannot tell us

Only 8 studies (486 patients); short follow-up (12-32 weeks); various GLP-1 drugs/doses; no meta-analysis; excludes newest agents; long-term safety and reproductive outcomes not assessed.

How to read the evidence

This is a systematic review of longitudinal cohort studies, which represents strong evidence methodology. However, the small number of included studies (8) and moderate total sample size (486) limit the strength somewhat. No meta-analysis was performed.

When this study was published

Published in 2024, this is a recent systematic review covering studies from 2015-2022. It captures the evidence base for older GLP-1 drugs in PCOS but may not reflect the latest data on newer agents like high-dose semaglutide or tirzepatide.

The bigger picture

As GLP-1 drugs become more widely used for obesity and diabetes, their potential in PCOS is generating significant clinical interest. PCOS sits at the intersection of metabolic, reproductive, and endocrine dysfunction — exactly the kind of multi-system condition where GLP-1 drugs' broad metabolic effects could be most beneficial. Several ongoing clinical trials are evaluating newer GLP-1 drugs specifically for PCOS outcomes including fertility.

Questions still open

Do newer GLP-1 drugs like semaglutide or tirzepatide produce even greater improvements in PCOS parameters?
Does GLP-1-induced weight loss in PCOS actually improve fertility outcomes and pregnancy rates?
Is long-term GLP-1 therapy safe for reproductive-age women, and should it be stopped before pregnancy attempts?

Common questions

Can GLP-1 drugs like Ozempic help with PCOS?

This systematic review suggests yes — GLP-1 drugs effectively reduce body weight, BMI, waist circumference, and visceral fat in women with PCOS. Combining them with metformin appears to work even better. While not yet specifically approved for PCOS, many doctors are prescribing them off-label for PCOS patients who also have obesity or insulin resistance.

Is it better to take a GLP-1 drug alone or with metformin for PCOS?

Based on this review, the combination of GLP-1 drugs with metformin produced better results than either treatment alone for reducing body measurements like BMI and waist circumference. This makes sense because metformin and GLP-1 drugs work through different mechanisms — metformin primarily improves insulin sensitivity while GLP-1 drugs reduce appetite and improve glucose-dependent insulin release.

Read the original research

A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.

Women's health (London, England), 20, 17455057241234530

View on PubMed ↗Publisher’s paper ↗

Citation

Bader, Salwa; Bhatti, Rahila; Mussa, Bashair; Abusanana, Salah. (2024). A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.. Women's health (London, England), 20, 17455057241234530. https://doi.org/10.1177/17455057241234530